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We have previously described the expression cloning of nine Borrelia burgdorferi antigens, using rabbit serum
enriched for antibodies specific for infection-associated antigens, and determined that seven of these antigens
were associated with infectious B. burgdorferi strain B31. One of these infection-associated antigens encoded a
451-amino-acid putative lipoprotein containing 21 consecutive and invariant 9-amino-acid repeat sequences
near the amino terminus that we have designated VraA for virulent strain-associated repetitive antigen A. The
vraA locus (designated BBI16 by The Institute for Genomic Research) maps to one of the 28-kb linear plasmids
(designated lp28-4) that is not present in noninfectious strain B31 isolates. Subsequent PCR analysis of clonal
isolates of B. burgdorferi B31 from infected mouse skin revealed a clone that lacked only lp28-4. Southern blot
and Western blot analyses indicated that the lp28-4 and VraA proteins, respectively, were missing from this
clone. We have also determined that VraA is a surface-exposed protein based on protease accessibility assays
of intact whole cells. Furthermore, vraA expression is modestly derepressed when cells are grown at 37°C
relative to cells grown at 32°C, suggesting that VraA is, in part, a temperature-inducible antigen. Homologues
cross-reactive to B. burgdorferi B31 VraA, most with different molecular masses, were identified in several B.
burgdorferi sensu lato isolates, including B. andersonii, suggesting that the immunogenic epitope(s) present in
strain B31 VraA is conserved between Borrelia spp. In protection studies, only 8.3% of mice (1 of 12) immunized
with full-length recombinant VraA fused to glutathione S-transferase (GST) were susceptible to infectious
challenge with 102 B. burgdorferi strain B31, whereas naive mice or mice immunized with GST alone were
infected 40% or 63 to 67% (depending on tissues assayed) of the time, respectively. As such, the partial
protection elicited by VraA immunization provides an additional testable vaccine candidate to help protect
against Lyme borreliosis.
Infection by the Borrelia burgdorferi sensu lato complex is
spread via the bite of infected ticks and manifests initially as a
flu-like illness that, if untreated, can develop into a chronic
state consisting of arthritic and neurological complications (25,
41–43). In the United States, the prevailing isolate found in
areas where the disease is endemic is B. burgdorferi sensu
stricto, although other sensu lato isolates, such as B. andersonii
(7, 26), have recently been identified in Missouri and in several
Southern states, along with other Borrelia spp. identified in
Europe, Eurasia, and Japan (9, 30, 46). The worldwide distri-
bution of the Lyme disease spirochete and its associated mor-
bidity has provided the impetus to develop a vaccine to combat
this disease. A great amount of work has been devoted toward
testing the efficacy of various B. burgdorferi lipoproteins as
protective immunogens; these proteins include OspA, OspB,
OspC, OspD, OspE, and OspF and, more recently, DbpA and
DbpB (2, 11, 12, 15, 18, 19, 29, 47). OspA was initially tested as
a vaccine candidate based on its surface exposure and abun-
dance on in vitro-cultivated B. burgdorferi sensu stricto (3, 12).
In the laboratory, tick-infected animals do not generate a sig-
nificant antibody titer against OspA, suggesting that ospA is
not expressed in vivo, thereby implying that OspA vaccination
may not protect against natural B. burgdorferi infection (11, 27,
34). Consistent with this finding, humans infected with B. burg-
dorferi do not exhibit a high titer antibody response to OspA
early in infection (5). More recently, OspA has been purported
as an arthropod-specific vaccine (11); that is, antibody against
OspA binds and kills B. burgdorferi within the midgut of the
tick during the blood meal of the immunized host. OspA has
been evaluated as a protective immunogen in human trials, and
the results indicate that the vaccine has marked efficacy (36,
44). However, the vaccine requires multiple boosts since anti-
OspA titers may decrease over time. Because ospA is not
expressed in the infected host, B. burgdorferi infection does not
function as an immunological boost; as such, a preexisting high
titer to OspA is essential for clearance of the spirochetes from
the midgut of the tick. More recently, cross-reactivity between
OspA and human leukocyte function-associated antigen 1
(hLFA-1) suggests that immunization with OspA may contrib-
ute to an autoimmune disorder (17).
The limitations of the OspA vaccine highlight the need to
evaluate additional protective antigens, particularly those ex-
pressed in mammals, to protect against B. burgdorferi infection.
Along these lines, we have identified nine genetic loci of B.
burgdorferi that are preferentially recognized by rabbits that
have developed infection-derived immunity to low-passage,
virulent B. burgdorferi B31 (38). It is conceivable that subsets of
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these antigens are targets for borreliacidal antibodies and, as
such, may function as protective immunogens against B. burg-
dorferi. Consistent with this idea, one of the clones identified
encoded dbpA, which has recently been shown to function as a
protective immunogen (18, 19). Yet another of these clones
encodes a 451-amino-acid protein antigen that contains 21
consecutive and invariant 9-amino-acid repeats near its amino
terminus that we have designated VraA for virulent strain-
associated repetitive antigen A (designated BBI16 by The In-
stitute for Genomic Research [TIGR]; see the TIGR website
at http://www.tigr.org/tdb/CMR/gbb/htmls/SplashPage.html).
In this study we report that VraA is a surface exposed antigen
that is slightly induced in B. burgdorferi B31 at 37°C relative to
32°C. We also demonstrate that antibodies directed against
either full-length or the amino-terminal half of VraA recognize
antigens of various molecular masses in several B. burgdorferi
sensu lato isolates. Furthermore, we demonstrate that VraA
functions as a partially protective immunogen in the mouse
model of Lyme borreliosis.
MATERIALS AND METHODS
Bacteria and plasmids. B. burgdorferi sensu stricto strain B31 was used in the
majority of studies presented in this report unless otherwise indicated. All B.
burgdorferi sensu stricto and sensu lato isolates used in this study are listed in
Table 1. Most strains used were passaged no more than three times in vitro and
were subsequently isolated from infected rabbits or mice to determine their
infective phenotype unless otherwise indicated. B. burgdorferi sensu lato strains
were cultured in BSK II media supplemented with 6% normal rabbit serum
(Pel-Freez Biologicals, Rogers, Ark.) at 32°C in a 1% CO2 atmosphere as
previously outlined (38). Clonal isolates of B. burgdorferi were obtained by
plating diluted cultures into agarose overlays as previously described (24). Two
clones, designated MSK5 and MSK7, were obtained after intradermal inocula-
tion of mice with 103 B. burgdorferi strain B31 passage 3 and isolation of infected
skin at 2 weeks postinfection, followed by plating in BSK II agarose. The entire
plasmid profile of both MSK5 and MSK7 was determined by designing primer
pairs that were specific for each individual plasmid followed by resolution of the
amplimers by agarose gel electrophoresis (24).
Escherichia coli strains used in this study were DH5a (Gibco-BRL, Bethesda,
Md.), TOP10F9 (Invitrogen Corp., Carlsbad, Calif.), and BL21(DE3)pLysE (No-
vagen Corp., Madison, Wis.). All E. coli strains were grown in Luria-Bertani (LB)
broth at 37°C with aeration or on LB agar at 37°C. E. coli was grown with
appropriate antibiotics at the following concentrations: ampicillin at 100 mg/ml,
kanamycin at 50 mg/ml, and chloramphenicol at 50 mg/ml. All plasmids used and
constructed in this report are listed in Table 2.
PCR. PCR was conducted essentially as described elsewhere (24), and the
oligonucleotide primers used are listed in Table 2. Briefly, the template was
prepared by pelleting infectious B. burgdorferi B31 (fewer than four in vitro
passages) at 5,800 3 g for 10 min and washing it in an equal volume of phos-
phate-buffered saline (PBS), followed by centrifugation and resuspension in
sterile water to yield a final concentration of 5 3 106 B. burgdorferi per ml. The
sample was then boiled for 5 min, the insoluble material was pelleted by cen-
trifugation (16,000 3 g) for 2 min, and the supernatant was placed in a new tube.
A 1-ml volume (or a 5 3 106 cell equivalence) was then added to the PCR. In
some instances individual colonies of infectious B. burgdorferi were instead added
to the PCR. Each appropriate primer set, in a 1 ml volume and at a final
concentration of 0.2 mM per primer, was incubated with 1 ml of the appropriate
B. burgdorferi template and brought to a final volume of 20 ml by adding 2 ml of
sterile water and 16 ml of Gibco-BRL SuperMix (Gaithersburg, Md.) which
contains buffer, all deoxynucleotides, and Taq polymerase. Samples were then
denatured at 94°C for 1 min, followed by 35 cycles of the following: 94°C for 1
min, 50°C for 1 min, and 72°C for 2 min. Incubation at 72°C for 6 min served as
the final extension step in the reaction. Products were resolved on 0.8 to 1%
agarose gels buffered in Tris-acetate-EDTA containing 0.5 mg of ethidium bro-
mide per ml.
Construction of the GST-vraA fusion proteins. Three separate glutathione
S-transferase (GST)-VraA fusion proteins were constructed by using the oligo-
nucleotide primers listed in Table 3. A plasmid encoding a fusion of GST to
full-length, mature VraA that lacked the VraA leader peptide and the initial
cysteine residue was constructed by PCR amplification using the primers Sal/
GST-FL and Not/GST-FL in conjunction with B. burgdorferi template DNA as
indicated above (Sal and Not refer to SalI and NotI restriction enzyme sites
engineered at the 59 ends of the oligonucleotides; see Table 3). The Sal/GST-FL
and Not/GST-FL primers amplified a 1,302-bp vraA fragment, encoding the
mature VraA protein (i.e., minus the leader peptide), and this fragment was
subsequently cloned into the pCR2.1-TOPO vector (Invitrogen) and designated
pCRL3-FL. The ligated product was transformed into TOP10F9 cells (Invitro-
gen), and transformants were selected for on LB agar containing kanamycin and
X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) according to the
manufacturer’s instructions. White colonies (putative positives) were grown in
LB broth, and DNA was purified from these cells by alkaline lysis to screen for
those containing the desired insert.
Similar constructs were made using either the oligonucleotides Sal/GST-FL
TABLE 1. Borrelial strains used in this study
Strain Relevant characteristics Source or reference
B. burgdorferi sensu stricto
MSK5 B31, low passage Passage 2 infectious clonal isolate; obtained from infected mouse skin 24
MSK7 B31, low passage Passage 2 attenuated clonal isolate; obtained from infected mouse skin and
determined to be lp28-42
24
B31, high passage Passaged several hundred times; nonclonal and noninfectious 13
297, low passage Passage 3 nonclonal isolate; obtained from infected rabbit skin biopsy D. Foley et al.a
CA-2-87, low passage Passage 3 nonclonal isolate; obtained from infected rabbit skin biopsy D. Foley et al.
ECM-NY-86, low passage Passage 3 nonclonal isolate; obtained from infected rabbit skin biopsy D. Foley et al.
JD-1, low passage Passage 3 nonclonal isolate; obtained from infected rabbit skin biopsy D. Foley et al.
NT-1, low passage Passage 3 nonclonal isolate; obtained from infected rabbit skin biopsy D. Foley et al.
2872-2 Low-passage nonclonal isolate V. Sambrib
B. afzelii ACA-1, low passage Infectious nonclonal isolate S. Norrisc
B. garinii Ip90, low passage Infectious nonclonal isolate S. Norris
B. andersonii
MOD-3, low passage Infectious nonclonal isolate D. Foley et al.
MOD-5, low passage Infectious nonclonal isolate D. Foley et al.
MOD-6, low passage Infectious nonclonal isolate D. Foley et al.
a D. Foley, J. Miller, and M. Lovett, University of California, Los Angeles.
b V. Sambri, University of Bologna, Bologna, Italy.
c S. Norris, University of Texas Health Science Center, Houston.
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and Not/GST-NT or the oligonucleotides Sal/GST-CT and Not/GST-FL to PCR
amplify the amino-terminal and carboxy-terminal vraA domains, respectively.
The resulting PCR amplimers, 729 and 594 bp in size, were cloned into the
pCR2.1-TOPO vector and named pCRL3-NT (amino-terminal clone) and
pCRL3-CT (carboxy-terminal clone) accordingly (Table 2). Following digestion
with SalI and NotI, the various fragments were gel purified via phenol-chloro-
form extraction, precipitated, and ligated to plasmid pGEX-4T-1 restriction
digested with SalI and NotI. Ligated DNA was then transformed into DH5a
(Gibco-BRL) using standard methodologies. Transformants were screened for
inserts by subjecting clones to alkaline lysis followed by digestion with appropri-
ate restriction enzymes.
Purification of GST-VraA fusion proteins. A representative clone of the three
GST-VraA fusions, i.e., full-length VraA (residues 18 to 451 of VraA fused to
GST), the amino-terminal half (residues 18 to 260 of VraA fused to GST), and
the carboxy-terminal half (residues 253 to 451 of VraA fused to GST) were
transformed into BL21(DE3)pLysE (Novagen), and 2 liters of cells (with appro-
priate antibiotic selection) was grown to early log phase (optical density at 600
nm of 0.3 to 0.4). The same methodology was applied to each recombinant
GST-VraA fusion protein separately as outlined below. The appropriate GST-
VraA fusion protein was induced by the addition of 1 mM IPTG and subsequent
incubation for 2 h at 37°C. The resulting cells were pelleted by centrifugation at
6,000 3 g, resuspended in 40 ml of PBS (pH 7.4), and subjected to one cycle of
freezing and thawing to convert the cells to spheroplasts. The cells were then
subjected to two passages through the French pressure cell at 16,000 lb/in2. The
clarified supernatant was centrifuged at 3,000 3 g for 10 min to pellet the unlysed
E. coli, and the resulting supernatant was recentrifuged at 40,000 3 g for 20 min
to pellet the total membrane component of E. coli. After we determined that all
three forms of the GST-VraA fusion proteins were soluble upon induction, the
supernatants (i.e., soluble protein) were then separately added to glutathione-
Sepharose 4B beads and rocked gently overnight at 4°C to promote binding of
the GST-VraA fusion proteins to immobilized glutathione. After the overnight
incubation, the beads were pelleted at 500 3 g, the supernatant was removed,
and the beads were washed with 25 ml of PBS (pH 7.4). The wash step was
repeated and, following resuspension with PBS, the resulting suspension was
poured into a column and the column was washed with 25 ml of PBS. Following
the wash step, 5 mM reduced glutathione in PBS was added, and 1-ml column
fractions were collected. Fractions containing the various GST-VraA proteins
were identified by subjecting 2.5 ml of each fraction to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), followed by staining with Coo-
massie blue and destaining. Fractions containing the different recombinant GST-
VraA samples were further purified from low-molecular-weight contaminants by
preparative SDS-PAGE. Briefly, 1 mg of the given GST-VraA fusion protein was
resolved on a 16-cm-by-20-cm SDS-polyacrylamide gel (Bio-Rad, Richmond,
Calif.) with a 13-cm wide preparative gel comb, and the gel was stained with
Coomassie blue in double-distilled, sterile water. The band corresponding to the
appropriate GST-VraA molecule was excised from the gel and electroeluted
using the S&S Elutrap Electro-separation System from Schleicher & Schuell, Inc.
(Keene, N.H.) as outlined by the manufacturer.
Antibody production. Three separate rabbits were prebled and subsequently
immunized with each of the three affinity-purified GST-VraA fusion proteins
obtained. In all cases, 100 mg of the GST-VraA protein, in complete Freund
adjuvant, was injected subcutaneously (four sites, 25 mg per site). After 6 weeks,
the rabbits were boosted with 100 mg of the same GST-VraA protein in incom-
plete Freund’s adjuvant. Two weeks later the rabbits were bled to obtain serum
specific for either full-length VraA fused to GST, the amino-terminal half of
VraA fused to GST, or the carboxy-terminal half of VraA fused to GST. Each
serum was tested qualitatively by Western blotting to determine the specificity of
the antiserum for both homologous and heterologous forms of recombinant
GST-VraA, as well as native VraA (see below).
Protease accessibility. Protease accessibility studies were conducted as previ-
ously described (4) with the following modifications. B. burgdorferi B31 passage
7 cells (approximately 2 3 108) were centrifuged at 4,300 3 g for 15 min at 4°C,
the supernatant was removed, and the pellet was resuspended in an equal volume
of PBS (pH 7.4)–5 mM MgCl2–50 mM sucrose. The wash was repeated again,
TABLE 2. Plasmids used in this study
Plasmid Relevant characteristics Source
pCR2.1-TOPO TA cloning vector; Apr Kanr Invitrogen Corp., Carlsbad, Calif.
pGEX-4T-1 Vector used to make GST fusions to VraA; Apr Amersham Pharmacia Biotech
Inc., Piscataway, N.J.
pCRL3-FL 1,302-bp fragment, from PCR amplification using oligonucleotide primers Sal/GST-FL
and Not/GST-FL, cloned into pCR2.1-TOPO
This study
pCRL3-NT 729-bp fragment, from PCR amplification using oligonucleotide primers Sal/GST-FL
and Not/GST-NT, cloned into pCR2.1-TOPO
This study
pCRL3-CT 594-bp fragment, from PCR amplification using oligonucleotide primers Sal/GST-CT
and Not/GST-FL, cloned into pCR2.1-TOPO
This study
pL3-FL10 Full-length VraA construct residues 18 to 451 of VraA fused to GST (minus leader
peptide and initial cysteine residue; nucleotides 50 to 1352a of VraA fused in-frame
to GST sequence on pGEX-4T-1)
This study
pL3-NT3 Amino-terminal VraA construct residues 18 to 260 of VraA fused to GST (minus
leader peptide and initial cysteine residue; nucleotides 50 to 779b of VraA fused in-
frame to GST sequence on pGEX-4T-1)
This study
pL3-CT7 Carboxy-terminal VraA construct residues 253 to 451 of VraA fused to GST (minus
leader peptide and initial cysteine residue; nucleotides 758 to 1352c of VraA fused
in-frame to GST sequence on pGEX-4T-1)
This study
a See Table 3 for The oligonucleotides used; Sal/GST-FL and Not/GST-FL amplify full-length VraA.
b As in footnote a except oligonucleotides Sal/GST-FL and Not/GST-NT were used to amplify the amino-terminal half of VraA
c As in footnote a except oligonucleotides Sal/GST-FL and Not/GST-CT were used to amplify the carboxy-terminal half of VraA.
TABLE 3. Oligonucleotides used to PCR amplify vraA and vraA derivatives
Primer Sequence (59 to 39)a Position of vraAb
Sal/GST-FL ACGCGTCGACGCAGGCCGGATTTTAATATCGATC 50373
Not/GST-FL ACGCGCGGCCGCAGTTTATATTTTGACACTATAAGC 135231329
Not/GST-NT ACGCGCGGCCGCTCATTAGATAGCGTATTTTTTAG 7793757
Sal/GST-CT ACGCGTCGACTAAAAAATACGCTATCTAATGAT 7583780
a Underlined sequence indicates the SalI or NotI site; see primer name for restriction site used.
b Numbers refer to the TIGR designation of the BBI16 open reading frame; the arrow indicates the orientation of the oligonucleotide relative to the sense and
antisense strands of the vraA sequence. The repetitive domain of VraA is encoded by nucleotides 157 to 723 of vraA.
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and the samples were split into equal volumes. Either 50 ml of sterile water or
proteinase K (to a final concentration of 200 mg/ml) was added to each sample,
and both were incubated at 20°C for 40 min. After 40 min, phenylmethylsulfonyl
fluoride (PMSF) was added to a final concentration of 1 mM, and the samples
were examined by dark-field microscopy to assess their motility (i.e., as an
indirect test of viability). The samples were then centrifuged and washed again as
described above except that the solution also contained 1 mM PMSF. The final
pellets were resuspended in Laemmli sample buffer, and the proteins were
separated by SDS-PAGE and analyzed by immunoblotting as described below.
Growth phase induction of vraA. B. burgdorferi B31 MSK5 (passage 2) was
inoculated at an initial cell density of 5 3 105 per ml in BSK II media and was
grown in separate cultures at 32 and 37°C. Aliquots at different time points were
removed at the following cell densities in a volume equal to a final count of 108
B. burgdorferi cells (the numbers listed are approximate per-milliliter values): 5 3
106, 1 3 107, 2.5 3 107, 5 3 107, 1 3 108, 2 3 108, or 3 3 108 organisms. Each
sample was pelleted at 5,800 3 g for 20 min, washed in PBS (pH 7.4), and
resuspended in Laemmli sample buffer. Equivalent amounts of B. burgdorferi
whole-cell lysates per time point were resolved by SDS-PAGE, immunoblotted,
and probed with anti-VraA serum as described below.
pH induction of vraA. Experiments to determine whether vraA was pH induc-
ible were conducted as described by Carroll et al. (8).
SDS-PAGE and Western blotting. SDS-PAGE and Western blotting with the
different anti-GST-VraA sera was done essentially as described previously (38,
40). The dilution of anti-VraA serum used was 1:5,000 regardless of the GST-
VraA immunogen used to immunize rabbits. Rabbit anti-p66 serum was gener-
ously provided by Sven Bergstro¨m, Umeå University, and was diluted 1:5,000.
Mouse monoclonal antibody directed against B. burgdorferi endoflagella was
kindly provided by Alan Barbour, University of California at Irvine, and was used
at a 1:50 dilution. Protein A, conjugated to horseradish peroxidase, and diluted
1:1,000, was used to detect all immobilized immune complexes. Blots were
developed using Amersham’s enhanced chemiluminescence (ECL) system (Am-
ersham Pharmacia Biotech, Piscataway, N.J.).
Mouse immunization with VraA. Two groups of 24 8-week-old female C3H/
HeN mice (Charles River Laboratories, Inc., Wilmington, Mass.) were each
immunized with 25 mg of either GST or full-length VraA fused to GST (GST-
VraA FL). In addition, 24 naive mice served as controls for B. burgdorferi
infection. After 10 weeks, the mice were immunized with the same amount of
protein (with the exception of the untreated controls). Representative mice (four
were randomly chosen per group) were bled on day 15 postboost, and individual
sera were used in a Western blot assay to determine qualitatively whether the
animals had a humoral response to recombinant VraA. Since all sera from
immunized mice showed the appropriate reactivity to either GST or GST-VraA
at day 17 postimmunization, 12 mice per group were challenged with either 102
or 104 infectious B. burgdorferi B31 isolate MSK5 which contains all of the known
borrelial plasmids (as determined by PCR amplification [24]). At 2 weeks after
challenge, the mice were sacrificed and their abdomen skins, spleens, and blad-
ders were aseptically removed and cultured at 32°C in 10 ml of BSK II medium
supplemented with 6% normal rabbit serum. After 4 days, 0.5 ml of the culture
was passaged blindly into 10 ml of BSK II medium, and the samples incubated at
32°C. Protection was assessed by the absence of cultured B. burgdorferi from each
tissue sample (both the initial culture and the blindly passaged sample) out to a
6-week period.
Statistical analysis. A 332 contingency table and x2 test of independence
were used to test the null hypothesis, “Protection against B. burgdorferi challenge
is independent of the vaccinogen used.” The null hypothesis was rejected when
P values of ,0.05 were obtained, indicating statistical significance.
RESULTS
Sequence analysis of vraA. Previously we had identified nine
distinct proteins that were antigenic in infection-immune rab-
bits (38). One of these antigens showed extensive redundancy
at the nucleotide level. The complete nucleotide sequence
indicated that this locus contained a hydrophobic core se-
quence at the amino terminus connected to the putative leader
peptidase II cleavage sequence FLAC, suggesting that this
gene encoded a lipoprotein antigen. Further assessment of this
gene indicated that the mature domain contained a 27-bp
invariant, repetitive sequence, as shown in the Pustell DNA
matrix plot in Fig. 1A, that encodes the following primary
sequence: Glu-Glu-Glu-Leu-Lys-Lys-Lys-Gln-Gln. Elucida-
tion of the entire B. burgdorferi genome sequence by TIGR
corroborated our nucleotide sequence and indicated that this
genetic locus, named BBI16 by TIGR (see TIGR website and
also reference 14), was located on linear plasmid 28-4 (lp28-4).
Because of these repetitive domains, we have designated this
gene vraA for virulent strain-associated repetitive antigen A.
Although the predicted molecular mass of mature VraA (i.e.,
minus the putative amino-terminal leader peptide) is 52,375
Da, VraA migrates at an apparent molecular mass of approx-
imately 70 kDa, presumably due to the conformation of the
repetitive domain. This type of anomalous migration has been
observed previously in other repetitive proteins (33, 48). The
vraA locus (BBI16) is a member of a B. burgdorferi paralogous
family containing 17 genes (family 60; see TIGR website);
however, the homology between the paralogues resides pre-
dominantly within the predicted carboxy-terminal domain (i.e.,
no other paralogue contains a repetitive domain like that ob-
served in vraA). One of the paralogues, encoded by BBI28,
contains one imperfect copy of the repetitive domain observed
FIG. 1. Sequence analysis of vraA repetitive domain. (A) Pustell
DNA matrix analysis of vraA aligned against itself. Lines framing the
main diagonal show the location of the repetitive domain from nucle-
otides 157 through 723 of vraA encoding the 21 consecutive 9-amino-
acid repeat EEELKKKQQ. The number of lines above or below the
diagonal indicates the number of repeat units in vraA. The absence of
any breaks within the upper and lower diagonals demonstrates that the
repeats are consecutive and invariant. The short perpendicular line in
the lower right corner indicates a short imperfect inverted repeat
sequence located at nucleotides 1222 to 1240 of vraA. (B) Comparison
between the single region of homology of BBI28 and the vraA repeat
unit. Underlined nucleotides and amino acid indicate differences in the
vraA and BBI28 sequences, respectively.
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in vraA with 88% identity at the nucleotide level, resulting in a
single amino acid substitution relative to the repetitive domain
in VraA (Fig. 1B). With the noted exception of the single small
domain in BBI28, no homology is observed at the nucleotide or
amino acid level within the repetitive domains of vraA with any
other sequence in the database.
Production of antiserum specific for VraA. In order to ob-
tain sufficient amounts of recombinant VraA for immunization
purposes, we constructed a translational fusion of the gene
encoding GST to vraA using the pGEX-4T-1 vector as de-
scribed in the Materials and Methods section. After induction
of the fusion protein, the soluble component, containing the
GST fused to full-length VraA recombinant protein [GST-
VraA (FL)], was affinity purified using a glutathione-Sepha-
rose column (Fig. 2). The fusion protein shown in Fig. 2 rep-
resents a carboxy-terminal fusion to GST of residues 18 to 451
of VraA. Panel A shows the overproduction of VraA (lane 2)
relative to the induction of GST in the vector only control (lane
1). We then assessed the solubility of recombinant VraA and
found that it was associated essentially with the soluble com-
ponent (Fig. 2B, lane S) relative to the membrane fraction
(Fig. 2, lane M) when produced in E. coli. Affinity purification
resulted in a single pure fraction containing recombinant VraA
that we used for subsequent immunization and vaccination
studies (see below). We also made similar separate constructs
that joined residues 18 to 260 of VraA and residues 253 to 451
of VraA to GST, designated amino-terminal VraA and car-
boxy-terminal VraA, respectively, and purified these fusion
proteins to homogeneity (data not shown). Purified full-length,
amino-terminal, and carboxy-terminal VraA (all fused to GST)
were used to immunize rabbits separately, and the polyclonal
antiserum obtained was tested to confirm that these antibody
reagents were specific for VraA. Clonal isolates of B. burgdor-
feri B31, derived from infected C3H/HeN mouse skin, desig-
nated MSK5 and MSK7, were analyzed by SDS-PAGE and
Western blot with all three sera obtained. We have previously
determined that MSK5 contains all known plasmids, whereas
MSK7 is lacking lp28-4, the linear plasmid that encodes vraA
(24). As predicted, the MSK7 sample showed no immunore-
activity to the 70-kDa full-length VraA species when probed
either with serum against full-length VraA (Fig. 3B, lane 2) or
with serum directed against the amino- or carboxy-terminal
constructs (data not shown). In contrast, a 70-kDa antigen and
a probable 50-kDa degradation product was observed in MSK5
when probed with antiserum generated against rabbits im-
munized with either full-length (Fig. 3B, lane 1) or amino-
terminal (data not shown) VraA. However, no reactivity was
observed when serum from rabbits immunized with the car-
boxy-terminal half of VraA was used as the primary antibody
(data not shown). In all instances, sera directed against the
three different GST-VraA proteins contained antibodies reac-
tive with each homologous recombinant protein (data not
shown). This indicated that the rabbits immunized with GST
fused to either full-length, amino-terminal, or carboxy-termi-
nal VraA generated a humoral response specific for the ap-
propriate VraA construct. Since serum directed against the
carboxy-terminal half of VraA did not react with native VraA
from B. burgdorferi B31 and only weakly reacted with full-
length and amino-terminal recombinant VraA fused to GST, it
is most likely that the immunoreactivity observed is restricted
to the GST moiety (data not shown). As controls, we also
determined that neither rabbit preimmune serum nor anti-
serum to GST recognized any B. burgdorferi proteins, indicat-
ing that the immunoreactivity observed was restricted to VraA
(data not shown). Furthermore, infection derived rabbit serum
recognized full-length and amino-terminal recombinant VraA
fused to GST, but not carboxy-terminal VraA fused to GST
(data not shown). These results, taken together, suggest that
FIG. 2. Overproduction and purification of full-length VraA fused to GST. (A) Coomassie blue stain of an SDS–10% polyacrylamide gel
showing the overproduction of GST alone (lane 1) and full-length VraA fused to GST [GST-VraA(FL); lane 2, indicated by an arrow] following
IPTG (isopropyl-b-D-thiogalactopyranoside) induction as outlined in Materials and Methods. (B) Solubility of recombinant GST-VraA(FL). After
induction, E. coli cells synthesizing GST-VraA(FL) were subjected to breakage with a French pressure cell and the insoluble component cleared
by centrifugation as indicated in the Methods section. The resulting membrane material (M) and soluble component (S) were resolved by
SDS-PAGE, and the gel was stained with Coomassie blue. Note the appearance of an approximately 100-kDa species in the lane containing the
soluble fraction (lane S, indicated by an arrow). (C) Purified GST-VraA(FL). GST-VraA(FL) was affinity purified with glutathione-Sepharose
beads, electroeluted from an unfixed SDS-polyacrylamide gel to eliminate lower-molecular-mass contaminants, reseparated by SDS-PAGE, and
stained with Coomassie blue. Purified GST-VraA(FL) was then used to immunize both rabbits and mice to generate anti-VraA serum and in
protection studies, respectively. Numbers on the left refer to the molecular mass of protein markers (in kilodaltons).
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the repetitive domain is the predominant immunogenic com-
ponent of VraA.
Surface localization of VraA. To determine whether VraA
was a surface exposed antigen in B. burgdorferi B31, we made
changes to the protease accessibility methodology previously
published (4) inasmuch as B. burgdorferi began to clump and
were nonmotile after incubation in PBS (pH 7.4)–5 mM
MgCl2. Based on our previous experience with outer mem-
brane protein localization and outer membrane purification
studies (37, 39, 40), we hypothesized that the loss of motility
was due to the loss of the structural integrity of the B. burg-
dorferi outer membrane. B. burgdorferi cells were therefore
incubated in several different buffers, and their viability was
assessed as a function of motility. We found that B. burgdorferi
resuspended in PBS (pH 7.4)–5 mM MgCl2 containing 50 mM
sucrose was active and motile for periods of time exceeding 1 h
with or without added proteinase K. Under these conditions,
addition of proteinase K resulted in a near-complete reduction
of VraA (Fig. 4A), modified the surface exposed protein P66
(Oms66) (39) (Fig. 4B), but did not alter the levels of endofla-
gella (Fig. 4C), a known subsurface marker of spirochetal bac-
teria (4). This result implies that VraA is a surface-exposed
protein and that the B. burgdorferi cells were structurally intact,
respectively.
Temperature- and growth-phase-dependent induction of
vraA. We initially evaluated whether vraA was induced at 23,
32, and 37°C and found that VraA was overproduced at 37°C
(data not shown). However, subsequent studies to repeat this
observation yielded variable results. This led us to surmise that
vraA may be subjected to growth phase regulation, pH regu-
lation, or both. To assess this, cultures of infectious B. burg-
dorferi were inoculated at a density of 5 3 105 per ml, and
FIG. 3. Specificity of antiserum directed against full-length VraA. Whole-cell lysates of protein derived from B. burgdorferi B31 MSK5 (wild
type) and MSK7 (lp28-42) were separated by SDS-PAGE and stained with Coomassie blue (A) or immunoblotted and probed with rabbit serum
directed against full-length VraA fused to GST (B). Lane 1, MSK5; lane 2, MSK7. The numbers on the left refer to the molecular masses of the
protein markers (in kilodaltons).
FIG. 4. Surface Localization of VraA. Intact B. burgdorferi B31 MSK5 either left untreated (lane 1) or treated with proteinase K (lane 2),
resolved by SDS-PAGE, and immunoblotted. Identical blots were then probed with either anti-VraA (full-length VraA fused to GST) (A), anti-p66
(B), or anti-endoflagellum (C) serum. The numbers on the left refer to the molecular mass of protein markers (in kilodaltons).
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samples were taken at various time points commensurate with
early-, mid-, late-, and stationary-phase growth at both 32 and
37°C using a previously published methodology (21, 31). Iden-
tical amounts of protein for each time point were resolved by
SDS-PAGE and either stained with Coomassie blue (data not
shown) or immunoblotted to ensure that equivalent levels of B.
burgdorferi protein were present and to assess levels of VraA
synthesized at each time point, respectively. Our results, after
four independent experiments, indicate that VraA is only
slightly overproduced when cells are grown at 37°C and that
vraA expression is not affected by the growth phase of the
culture (Fig. 5). Additionally, VraA appears to be proteolyti-
cally degraded more efficiently at 37°C as seen by the increase
in the approximate 50-kDa degradation product, perhaps due
to the induction of a temperature-dependent protease (Fig. 5).
Alternatively, it is possible that the 50-kDa degradation prod-
uct accumulates at 37°C due to decreased proteolysis of this
lower-molecular-weight species independent of full-length
VraA. Only three samples, at various growth phases, ranging
from approximately 1 3 107 (Fig. 5, lanes 1 and 2) to 3 3 108
cells (Fig. 5, lanes 5 and 6), are shown in Fig. 5; however, other
intermediate samples at different growth phases were also eval-
uated and yielded identical immunoblot profiles at 32 and 37°C
relative to the samples shown in Fig. 5 (data not shown). These
results, taken together, indicate that vraA expression is not
regulated by growth phase.
We also determined whether vraA was pH inducible inas-
much as the levels of VraA produced could be increased under
conditions where the BSK II culture medium would be acidi-
fied. Using the protocol outlined by Carroll et al. (8), we did
not see induction of vraA when cells were incubated at pH 6.0
relative to cells cultivated at pH 7.0 or pH 8.0 (data not
shown), indicating that pH has no direct or indirect effect on
vraA expression.
Although we were not able to demonstrate induction of vraA
in these various analyses, these results do not preclude the
possibility that vraA is derepressed in either infected mammals
or arthropod vectors (or both) in response to host-specific
signals that have not been effectively simulated in our in vitro
based studies.
VraA confers partial protection in mice. To test whether
VraA could function as a protective immunogen, we immu-
nized 24 C3H/HeN mice with recombinant full-length VraA
fused to GST, i.e., GST-VraA(FL) (FL represents full length)
as described in Materials and Methods. The controls used
included 24 mice immunized with GST alone and 24 naive
mice. Prior to the challenge, we collected serum from several
randomly chosen mice to qualitatively test whether a humoral
response had been generated against the appropriate immuno-
gen [GST or GST-VraA(FL)]. In all cases, mice immunized
with GST or GST-VraA(FL) generated antibodies to the ap-
propriate antigen, respectively (data not shown). Twelve mice
from each set were needle challenged with either 102 or 104 of
a clonal isolate of B. burgdorferi B31 MSK5 passage 3 that
contains all known B. burgdorferi plasmids (24). The results
indicated that nearly all of the mice challenged with 104 infec-
tious B. burgdorferi were susceptible regardless of the immuno-
gen given (Table 4). In contrast, only 8.3% (1 of 12) of the mice
immunized with GST-VraA(FL) were infected when chal-
lenged with 102 B. burgdorferi (Table 4), whereas the naive and
GST-immunized controls were infected 40% and 63 to 67% of
the time (depending on the infected tissue assessed), respec-
tively (Table 4). To assess statistical significance, a 332 con-
tingency table was used to test the null hypothesis “Protection
against B. burgdorferi challenge is independent of the vaccino-
gen used.” Values corresponding to skin samples obtained
using a 102 challenge inoculum were used in this analysis. The
calculated x2 of 8.67 exceeded that of x20.025,2 of 7.378, so the
null hypothesis was rejected (0.01 , P , 0.025; see Table 4),
indicating that the protection observed in the VraA immunized
mice was statistically significant. Similar results were obtained
FIG. 5. vraA induction at 37°C relative to 32°C. B. burgdorferi B31
MSK5 (passage 2) was inoculated at an initial cell density of 5 3 105
per ml in BSK II medium and cultivated as outlined in Materials and
Methods at both 32 and 37°C. At various phases of growth, samples
were removed and protein from whole-cell lysates was subjected to
SDS-PAGE and immunoblotting with anti-VraA serum. Lane 1,
1.25 3 107 B. burgdorferi grown at 37°C; lane 2, 1.9 3 107 B. burgdorferi
grown at 32°C; lane 3, 1.22 3 108 B. burgdorferi grown at 37°C; lane 4,
1.37 3 108 B. burgdorferi grown at 32°C; lane 5, 3.14 3 108 B. burg-
dorferi grown at 37°C; lane 6, 3.1 3 108 B. burgdorferi grown at 32°C.
The numbers on the left refer to the molecular mass of protein mark-
ers (in kilodaltons).
TABLE 4. Protection of C3H/HeN mice immunized
with recombinant VraAa
Immunogenb Challenge dose
c
(CFU)
No. of culture-positive samples/
total no. of samples testedd
in C3H/HeN tissues
Skin Bladder Spleen
None or naive 104 11/12 12/12 12/12
GST 104 11/12 11/12 11/12
GST-VraA 104 10/12 10/11 11/12
None or naive 102 4/10 4/10 4/10
GST 102 8/12 8/12 7/11
GST-VraA 102 1/12e 1/12e 1/11f
a The data reflect results from two independent immunization experiments.
b Mice were immunized with 25 mg of either GST or GST-VraA and boosted
4 weeks later with an equivalent amount of protein. After 2 weeks the mice were
bled and tested for antibody response against the appropriate antigen. Animals
were then challenged with the inoculum indicated.
c Mice were challenged intradermally with B. burgdorferi B31 MSK5 of the
high-infectivity phenotype at the inoculum size indicated.
d Equal numbers of mice were used for each group. Values of less than 12
indicate liquid culture contamination that did not support B. burgdorferi growth.
e x2 analysis indicates a significant difference from naive and GST immunized
mice (0.01 , P , 0.025).
f x2 analysis indicates a difference from naive and GST immunized mice
(0.05 , P , 0.1).
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with bladder tissue and, to a lesser extent, spleen tissue (see
Table 4).
Cross-reactivity of VraA antiserum against B. burgdorferi
sensu lato isolates. To determine whether other Borrelia spp.
encoded a homologue of VraA, we tested protein lysates for
reactivity to antiserum directed against full-length strain B31
VraA in a Western blot assay. All B. burgdorferi sensu stricto
isolates encoded a cross-reactive VraA-like antigen; however,
only strain ECM-NY-86 encoded an antigen of the same mo-
lecular mass as that of strain B31 VraA (Fig. 6; note a similar
immunoreactive band in both lanes 1 and 5). In contrast,
strains 297, JD-1, and NT-1 (Fig. 6, lanes 3, 6, and 7, respec-
tively) encoded antigens that were weakly reactive (only visible
after long exposures; not seen in Fig. 6) and larger in molecular
mass relative to strain B31 VraA, whereas strains CA-2-87 and
2872-2 (Fig. 6, lanes 4 and 12, respectively) produced strongly
reactive homologues that were smaller in molecular mass.
Some B. burgdorferi sensu lato isolates such as B. garinii strain
Ip90, did not encode a VraA-like molecule, whereas others
(Fig. 6, lane 11), including B. afzelii ACA1 (data not shown)
and B. andersonii strain MOD-3, MOD-5, and MOD-6, did
synthesize reactive homologues (Fig. 6, lanes 8 to 10, respec-
tively). Interestingly, B. andersonii encoded multiple, highly
reactive antigens. These strains were obtained from infected
rabbit skin samples and represent a polyclonal population.
Therefore, the profile observed for these samples may reflect
multiple genetic loci that encode VraA-like molecules that are
either present in each individual bacterium or a subset of
individual clones within the polyclonal pool tested. The reac-
tivity observed for antiserum against full-length VraA was
identical to that seen for reactivity against the amino-terminal
half of VraA, which is composed mostly of the repetitive do-
main. In contrast, little or no reactivity was seen for the anti-
serum generated against the carboxy-terminal half of VraA,
implying that the cross-reactivity between the VraA homo-
logues is mediated via the antigenicity of the repetitive motifs
(data not shown).
DISCUSSION
In this report we describe the characterization of a sur-
face-exposed repetitive motif containing antigen, designated
VraA, that we originally identified as an infection associated
antigen in infection immune rabbits from B. burgdorferi
sensu stricto strain B31 (13, 38). The most striking feature of
the vraA locus was the number of completely conserved
27-bp repeats encoding an invariant 9-amino-acid repetitive
motif (see Fig. 1). Unlike other antigens, such as the Bdr
proteins of Borrelia spp. (32, 51), the Vlp repetitive antigens
of Mycoplasma spp. (10, 33), and various proteins from
Plasmodium spp. (16, 22, 23), that contain repetitive do-
mains, the repetition in vraA is absolute at the nucleotide
level, suggesting that this conservation is important in main-
taining some as-yet-unknown function essential for maximal
infectivity. Alternatively, the repeat units may represent a
site for recombination resulting in antigenic variation or
slipped strand mispairing resulting in either antigenic or
phase variants. By analogy to other prokaryotic systems,
notably the Vlp proteins of Mycoplasma spp. (33, 48) and
the Opa antigens of Neisseria spp. (6, 28), VraA may change
its antigenicity by varying its length via slipped-strand mis-
pairing. This change in length has been shown previously to
change the antigenicity of Mycoplasma Vlp antigens (33, 48)
and cell-wall-associated proteins from gram-positive bacte-
ria (20). This antigenic variation could aid in immune eva-
sion resulting in persistent B. burgdorferi infection. Specifi-
cally, the repeat region of vraA contains a stretch of six
consecutive adenine nucleotides (within a region containing
adenines at 15 of 18 locations). A single mismatch within
this mononucleotide repetitive domain would yield an anti-
gen with either a modified repetitive primary sequence that
would be truncated soon after the repeats or a variant that
was abbreviated almost immediately (i.e., a stop codon in-
troduced within a repeat unit). In either case, the resulting
modified forms might exhibit reduced or nullified antigenic-
ity. The location of this change, i.e., which repeat unit is
FIG. 6. Presence of VraA or VraA homologues in various B. burgdorferi sensu lato isolates. Whole-cell lysates from B. burgdorferi sensu stricto
strain B31 passage 4 (lane 1), strain B31 passage 47 (lane 2), strain 297 (lane 3), strain CA-2-87 (lane 4), strain ECM-NY-86 (lane 5), strain JD-1
(lane 6), strain NT-1 (lane 7), and strain 2872-2 (lane 12) were resolved by SDS-PAGE along with B. andersonii strains MOD3, MOD5, and MOD6
(lanes 8 to 10) and B. garinii strain IP-90 (lane 11). All isolates with the exception of the strain B31 isolates were passaged two times in vitro. The
resulting gels were either stained with Coomassie blue (A) or immunoblotted and probed with anti-VraA serum (B). The numbers on the left refer
to the molecular mass of protein markers (in kilodaltons).
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modified, would dictate whether any of the repeats in native
VraA would be synthesized and to what degree the trun-
cated variants might cross-react with antibodies directed
against full-length VraA. This could, in part, explain the
resistance to infectious challenge with 100 low-passage B.
burgdorferi observed in 1 of the 12 mice immunized with
recombinant VraA (Table 4). That is, if a subpopulation of
our inoculum changed such that VraA was either antigeni-
cally modified by the increased or decreased length in the
number of repeats or by frameshift mutations within the
repeat units that resulted in truncated antigenic variants,
then B. burgdorferi encoding these proteins may not be killed
by antibody directed against “full-length” recombinant
VraA. To date, no evidence of such changes in native VraA
have been observed in B. burgdorferi B31 inasmuch as the
frequency of these changes may be similar to that seen in
other systems (approximately 1023 to 1024 [6, 28]). How-
ever, we have recently determined that variants of vraA are
present in in vitro-cultivated B. burgdorferi B31 that have
additional repetitive domains (i.e., greater than 21 in num-
ber; K. L. Swingle and J. T. Skare, unpublished data), sug-
gesting that VraA may be an antigenically variable protein.
Additionally, as seen in Fig. 6, other sensu stricto isolates
synthesize putative homologues relative to strain B31 that
may represent putative variants of B. burgdorferi sensu
stricto VraA. The changes predicted for these variants may
occur more frequently in vivo (i.e., within an infected ani-
mal) not unlike what has been shown for both the vlsE (49,
50) and ospEF-related (erp) loci (45), whose changes occur
exclusively during infection. A more detailed analysis of the
strain B31 vraA variants and its requisite homologues should
indicate whether this hypothesis is valid.
An important consideration related to protective immu-
nity in B. burgdorferi is the form in which the challenge
inoculum is delivered. Recently, it has become apparent that
host-adapted B. burgdorferi repress or derepress several
genes, notably, ospA or ospC, respectively (34), in the dis-
parate environments that B. burgdorferi occupies (i.e., ticks
versus mammals), as well as under experimental ex vivo
conditions (27). B. burgdorferi is present at very low levels
during mammalian infection; therefore the ability to evalu-
ate gene expression in vivo has required the implementation
of indirect methodologies (38). To circumvent this dilemma,
Akins et al. have demonstrated recently that B. burgdorferi
synthesizes a subset of proteins and/or antigens in dialysis
membrane chambers that are implanted within the perito-
neal cavity of rats (1). Although temperature certainly up-
regulates some B. burgdorferi genes, clearly other host sig-
nals were required for expression of some of the gene
products observed in this model system (1). Our results
indicate that a temperature shift in vitro results in the mod-
est induction of VraA (Fig. 5). Previous studies indicated
that the growth phase is also an important consideration for
assessing gene regulation in B. burgdorferi. Specifically,
OspC and BmpD are regulated in the transition from loga-
rithmic-phase growth to stationary-phase growth (21, 31).
However, in contrast, our data indicate that VraA is not
subject to growth phase regulation (Fig. 5 and data not
shown). It is conceivable that vraA may be expressed at high
levels in vivo (i.e., within the arthropod vector or mamma-
lian hosts) where nutrients and other important cofactors
may be limiting. Whether vraA is subject to such regulation
remains to be determined.
Shang et al. recently demonstrated that rabbits immu-
nized with outer membrane vesicles containing surface pro-
teins were protected only when challenged with in vitro
cultivated B. burgdorferi; rabbits challenged with skin biop-
sies containing host-adapted B. burgdorferi were infected in
a manner indistinguishable from naive controls (35). One
explanation could be alternative gene expression; that is, the
expression of new antigens within the infected mammal that
are not expressed during in vitro cultivation. Another viable
possibility is that B. burgdorferi changes antigens expressed
during in vitro cultivation (i.e., antigenic variation) or uses
other mechanisms, including phase variation, to alter their
antigenic profile. Once inside the host, this effect could
manifest in a polyclonal manner such that each B. burgdor-
feri cell may express a different form of a given antigen, such
as VlsE (49, 50) or OspEF (45) or different antigens in
various combinations. This hypothesis may, in part, explain
the presence of numerous paralogous gene families. Such
genetic paralogues may therefore be involved in immune
evasion independent of function. The vraA locus belongs to
one such paralogous family (family 60; see TIGR website).
However, in contrast to the other family members, vraA is
the only family member that contains the aforementioned
repeat units with the notable exception of the protein en-
coded by BBI28, which contains a similar but nonidentical
single repeat unit relative to VraA (see Fig. 1).
The absolute nature of the repetitive domains at both the
nucleotide and the amino acid level suggests an important
role for this motif. One possible explanation could be re-
lated to an increased avidity of VraA for a target ligand. In
this regard, we have no indication that VraA functions as an
adhesin in either arthropod or mammalian structures. Al-
ternatively, these repeats may serve as an immunological
“smokescreen,” as has been proposed for several Plasmo-
dium antigens (22). If so, then the epitope(s) defined by
these repeat units would theoretically mediate a robust yet
nonprotective response. Our immunization results, indicat-
ing partial protection to needle challenge, argue against
this; however, the possibility that the repeats of strain B31
VraA change in length in a manner analogous to that ob-
served in other B. burgdorferi sensu lato isolates (see Fig. 6),
resulting in antigenic variation, suggest that a strong im-
mune response to a single form of VraA may not protect in
all cases. Heterologous challenge against animals immu-
nized with B. burgdorferi B31 VraA could decipher this;
these studies and others to determine whether VraA is sub-
ject to phase and/or antigenic variation are in progress.
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